Tear Cytokine Signature in Vernal Keratoconjunctivitis: A Chemokine-Remodeling Axis Associated with Disease Severity
International Journal of Molecular Sciences · 11.08.2026 · 27 (16) · 7180
DOI: 10.3390/ijms27167180 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.08.2026. Verfasst von Kartik Goel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Eicher Shroff Centre for Stem Cell Research, Dr. Shroff's Charity Eye Hospital, New Delhi 110002, India. Hauptthemen laut MEDLINE: Conjunctivitis, Allergic, Tears, Cytokines, Chemokines. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Velux Stiftung, Department of Biotechnology, Centre for Rare and Unknown Eye Disorders.
Abstract (Originalsprache)
Vernal keratoconjunctivitis (VKC) is a chronic pediatric ocular allergy that can progress from seasonal to persistent inflammation with vision-threatening complications. Although Th2-associated mechanisms have been implicated, the immune correlates of disease severity are not well defined. Tear samples from VKC patients (moderate intermittent and moderate persistent) and healthy controls were collected using Schirmer’s strips. Cytokine profiling was performed using the OLINK® Target 48 Cytokine Panel. Differential expression, correlation with clinical features, and pathway enrichment analyses were performed. Compared to control, IL-15, CXCL11, CXCL9, MMP12, and CCL13 were significantly elevated in VKC, with higher levels in the persistent phenotype. These cytokines correlated with symptom duration, limbal involvement, and papillary hypertrophy. Pathway analysis revealed enrichment of IL-17, JAK–STAT, and chemokine signaling pathways. VKC severity is associated with distinct tear cytokine signatures, with the persistent phenotype showing enhanced chronic inflammatory signaling. These findings identify candidate tear-based markers of disease severity that require validation in larger, independent, and longitudinal cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eicher Shroff Centre for Stem Cell Research, Dr. Shroff's Charity Eye Hospital, New Delhi 110002, India.
- Department of Ocular Genetics and Centre for Unknown and Rare Eye Diseases, Dr. Shroff's Charity Eye Hospital, New Delhi 110002, India.
- College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
- Department of Pediatric Ophthalmology, Strabismus and Neuro-Ophthalmology, Dr. Shroff's Charity Eye Hospital, New Delhi 110002, India.
- Department of Surgical Biotechnology, Division of Surgery and Interventional Science, University College London, London NW3 2PS, UK.
- Department of Cornea and Anterior Segment Services, Dr. Shroff's Charity Eye Hospital, New Delhi 110002, India.
ORCID-Profile: Kartik Goel, Prisha Warikoo, Hirak Patra, Virender Singh Sangwan
Förderung
- Velux Stiftung
- Department of Biotechnology
- Centre for Rare and Unknown Eye Disorders
- Eicher Shroff Centre for Stem Cell Research
Zitieren
APA
Goel, K., Sapra, M., Warikoo, P., Tibrewal, S., Patra, H., Sangwan, V. S., Gour, A., & Tiwari, A. (2026). Tear Cytokine Signature in Vernal Keratoconjunctivitis: A Chemokine-Remodeling Axis Associated with Disease Severity. International Journal of Molecular Sciences, 27(16), 7180. https://doi.org/10.3390/ijms27167180
Vancouver
Goel K, Sapra M, Warikoo P, Tibrewal S, Patra H, Sangwan VS, et al. Tear Cytokine Signature in Vernal Keratoconjunctivitis: A Chemokine-Remodeling Axis Associated with Disease Severity. International Journal of Molecular Sciences. 2026;27(16):7180. doi:10.3390/ijms27167180
BibTeX
@article{Goel2026,
author = {Goel, Kartik and Sapra, Mehak and Warikoo, Prisha and Tibrewal, Shailja and Patra, Hirak and Sangwan, Virender Singh and Gour, Abha and Tiwari, Anil},
title = {Tear Cytokine Signature in Vernal Keratoconjunctivitis: A Chemokine-Remodeling Axis Associated with Disease Severity},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {16},
pages = {7180},
doi = {10.3390/ijms27167180}
}
EUVIMED